Legal & General Group
ORKA

Legal & General Group’s Oruka Therapeutics ORKA Stock Holding History

Legal & General Group’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$781K Sell
15,918
-2,826
-15% -$98.2K ﹤0.01% 2217
2025
Q4 		$568K Buy
18,744
+16,267
+657% +$453K ﹤0.01% 2389
2025
Q3 		$47.6K Hold
2,477
– – ﹤0.01% 2744
2025
Q2 		$27.8K Buy
+2,477
New +$25.8K ﹤0.01% 2880

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Legal & General Group's ORKA Position: Q1 2026 in Review

Legal & General Group reduced its Oruka Therapeutics (ORKA) stake by 15% in Q1 2026, selling an estimated $98.2K and leaving 15,918 shares worth $781K. The position accounts for ﹤0.01% of the portfolio, ranked #2217.

Legal & General Group first reported a position in ORKA in Q2 2025 and has held it in 4 quarters since. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Legal & General Group held 15,918 shares of Oruka Therapeutics worth $781K as of Q1 2026.
  • Legal & General Group sold 2,826 Oruka Therapeutics shares in Q1 2026, an estimated $98.2K.
  • Oruka Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2217 holding.
  • Legal & General Group first reported a position in Oruka Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.